In vitro inhibition of simvastatin metabolism, a HMG-CoA reductase inhibitor in human and rat liver by bergamottin, a component of grapefruit juice

European Journal of Pharmaceutical Sciences

Volumn 18, Issue 1, 2003, Pages 31-35

  Le Goff Klein, Nathalie ^a   Koffel, Jean Claude ^a   Jung, Louis ^a   Ubeaud, Geneviève ^a  

^a UNIVERSITÉ DE STRASBOURG   (France)

Author keywords

Bergamottin; CYP 450; Grapefruit juice; Inhibition; Metabolism; Naringenin; Simvastatin

Indexed keywords

BIODIVERSITY; DRUG INTERACTIONS; ENZYMES; METABOLISM;

DRUG METABOLISM;

DRUG PRODUCTS;

BERGAMOTTIN; FUROCOUMARIN DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; ISOENZYME; NARINGENIN; SIMVASTATIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; GRAPEFRUIT JUICE; HUMAN; IN VITRO STUDY; LIVER CELL; LIVER METABOLISM; LIVER MICROSOME; NONHUMAN; PRIORITY JOURNAL; RAT; SPECIES COMPARISON; SPECIES DIFFERENCE; STATISTICAL ANALYSIS;

ANIMALS; BEVERAGES; CITRUS PARADISI; FLAVANONES; FOOD-DRUG INTERACTIONS; HEPATOCYTES; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; LIVER; MICROSOMES, LIVER; PSORALENS; RATS; SIMVASTATIN;

EID: 0037240386     PISSN: 09280987     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0928-0987(02)00222-1     Document Type: Article

References (24)

1. Alberts A.W., Chen J., Kuron G., Hunt V., Huff J., Hoffman C., Rothrock J., Lopez M., Joshua H., Harris E., Patchett A., Monaghan R., Currie S., Stapley E., Albers-Schonberg G., Hensens O., Hirshfield J., Hoogsteen K., Liesch J., Springer J. Mevinolin: a highly potent competitive inhibitor of hydroxymethylglutaryl-coenzyme A reductase and a cholesterol-lowering agent. Proc. Natl. Acad. Sci. USA. 77:1980;3957-3961.
2. Bailey D., Malcolm J., Arnold O., Spence D. Grapefruit juice-drug interactions. Br. J. Clin. Pharmacol. 46:1998;101-110.
3. Benton R.E., Honig P.K., Zamani H., Cantilena L.R., Woosley R.L. Grapefruit juice alters terfenadine pharmacokinetics resulting in prolongation of repolarization on the electrocardiogram. Clin. Pharmacol. Ther. 59:1996;383-388.
4. Bogman K., Peyer A.K., Török M., Kuster E., Drewe J. HMG-CoA reductase inhibitors and P-glycoprotein modulation. Br. J. Pharmacol. 132:2001;1183-1192.
5. Bourrié M., Meunier V., Berger Y., Fabre G. Cytochrome P450 isoform inhibitors as a tool for investigation of metabolic reactions catalyzed by human liver microsomes. J. Pharmacol. Exp. Ther. 277:1996;321-332.
6. Condorcet D. Transformation and Estimating Michaelis-Menten Parameters. 1996;GMP, Paris. Abstract.
7. Di Marco M.P., Edwards D.J., Wainer I.W., Ducharma M.P. The effect of grapefruit juice and seville orange juice on the pharmacokinetics of dextromethorphan: the role of gut CYP3A and P-glycoprotein. Life Sci. 71:2002;1149-1160.
8. Fuhr U., Klittich K., Staib A.H. Inhibitory effect of grapefruit juice and its bitter principal naringenin on CYP1A2 dependent metabolism of caffeine in man. Br. J. Clin. Pharmacol. 35:1993;431-436.
9. Fukuda K., Guo L., Ohashi N., Yoshikawa M., Yamazoe Y. Amounts and variation in grapefruit juice of the main components causing grapefruit-drug interaction. J. Chromatogr. B. 741:2000;195-203.
10. Ho P., Ghose K., Saville D., Wanwimolruk S. Effect of grapefruit juice on pharmacokinetics and pharmacodynamics of verapamil enantiomers in healthy volunteers. Eur. J. Clin. Pharmacol. 56:2000;693-698.
11. Ho P., Saville D., Coville P., Wanwimolruk S. Content of CYP 3A4 inhibitors, naringin, naringenin and bergapten in grapefruit juice and grapefruit juice products. Pharm. Acta Helv. 74:2000;379-385.
12. Josefsson M., Zackrisson A.L., Ahlner J. Effect of grapefruit juice on the pharmacokinetics of amlodipine in healthy volunteers. Eur. J. Clin. Pharmacol. 51:1996;189-193.
13. i in a competitive enzyme-inhibition model: comparisons among three methods of data analysis. Drug. Metab. Dispos. 27:1999;756-762.
14. Kupferschmidt H., Ha H.R., Ziegler H., Meier P., Krähenbühl S. Interaction between grapefruit juice and oral midazolam in humans. Clin. Pharmacol. Ther. 58:1995;20-28.
15. Kupferschmidt H., Fattinger K.E., Ha H.R., Follath F., Krahenbuhl S. Grapefruit juice enhances the bioavailability of the HIV protease inhibitor saquinavir in man. Br. J. Clin. Pharmacol. 45:1998;355-359.
16. Lilja J., Kivisto K., Neuvonen P. Duration of effect of grapefruit juice on the pharmacokinetics of the CYP 3A4 substrate simvastatin. Clin. Pharmacol. Ther. 68:2000;384-390.
17. Mauro V.F. Clinical pharmacokinetics and practical applications of simvastatin. Clin. Pharmacokinet. 24:1993;195-202.
18. Miniscalco A., Lundahl A.L., Regardh C.G., Edgar B., Erikson U.G. Inhibition of dihydropyridine metabolism in rat and human liver microsomes by flavonoids found in grapefruit juice. Pharmacol. Exp. Ther. 261:1992;1195-1199.
19. Prueksaritanont T.L., Gorham M., Ma B., Liu L., Yu X., Zhao J., Slaugter D.E., Arison B.H., Vyas K.P. In vitro metabolism of simvastatin in humans [SBT] identification of metabolising enzymes and effect of the drug on hepatics P450S. Drug. Metab. Dispos. 25:1997;1191-1199.
20. Spahn-Langguth H., Langguth P. Grapefruit juice enhances intestinal absorption of the P-glycoprotein substrate talinolol. Eur. J. Pharm. Sci. 12:2001;361-367.
21. Ubeaud G., Hagenbach J., Vandenschrieck S., Jung L., Koffel J.C. In vitro inhibition of simvastatin metabolism in rat and human liver by naringenin. Life Sci. 65:1999;1403-1412.
22. Voet D., Voet J. Rates of enzymatic reaction. Biochemistry. 1990;342-344 John Wiley, New York.
23. Wu X., Whitfield L.R., Stewart B.H. Atorvastatin transport in the caco-2 cell model: contributions of P-glycoprotein and the proton-monocarboxylic acid co-transporter. Pharm. Res. 17:2000;209-215.
24. Yee G.C., Stanley D.L., Pessa L.J., Dalla Costa T., Beltz S.E., Ruiz J., Lowenthal D.T. Effect of grapefruit juice on blood cyclosporin concentration. Lancet. 345:1995;955-956.